Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2017-03-31 AGM Information
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
3_ THR AGM2017 ShareholdersRights (NL).pdf
AGM Information Classification · 98% confidence The document text explicitly discusses procedures and rights related to an upcoming 'jaarvergadering' (Annual General Meeting) scheduled for Tuesday, May 2, 2017. Key elements include the right of shareholders to place items on the agenda, submit resolutions, and submit written questions prior to the meeting. This content directly relates to the preparation and information dissemination for an AGM. Since the document details the rights and procedures for shareholder participation and voting agenda setting for the AGM, it aligns best with the 'AGM Information' category (AGM-R), rather than a proxy statement (PSI) or voting results (DVA), as it precedes the meeting itself.
2017-03-31 Dutch
1_THR AGM2017 Convocation Notice (ENG).pdf
AGM Information Classification · 100% confidence The document is explicitly titled 'CONVOCATION OF THE ANNUAL GENERAL SHAREHOLDERS' MEETING' and details the agenda, proposed resolutions, voting procedures, and admission requirements for a meeting scheduled for May 2, 2017. This content directly relates to the formal notice and materials surrounding an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2017-03-31 English
1_THR AGM2017 ConveningNotice (NL).pdf
AGM Information Classification · 99% confidence The document is explicitly titled "OPROEPING TOT DE JAARVERGADERING VAN AANDEELHOUDERS" (Call for the Annual General Meeting of Shareholders) and details the agenda, voting procedures, registration deadlines, and requirements for participation in a meeting scheduled for May 2, 2017. The agenda items cover the review of the annual report, approval of the remuneration report, and discharge of directors, which are standard procedures for an AGM. This content directly corresponds to the definition of AGM Information.
2017-03-31 Dutch
5_Thrombo_010_Jaarverslag_2016EN_014_singles.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT' and contains comprehensive sections including a message from the CEO, management reports, corporate governance, consolidated annual accounts, and the statutory auditor's report for the fiscal year 2016. It covers the full financial performance and activities of the company, fitting the definition of an Annual Report (10-K). FY 2016
2017-03-31 English
5_Thrombo_Jaarverslag_2016NL.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'FINANCIËLE INFORMATIE 2016' and contains a comprehensive table of contents for an 'Jaarverslag' (Annual Report). It includes sections for the CEO's foreword, management reports, corporate governance, consolidated financial statements (balance sheet, income statement, cash flow), and the auditor's report. The document length is substantial (over 300,000 characters), confirming it is the full annual report rather than an announcement or summary. Therefore, it is classified as an Annual Report (10-K). FY 2016
2017-03-31 Dutch
17-THR-02- FY16_FINAL EN.pdf
Earnings Release Classification · 95% confidence The document is titled "ThromboGenics Business Update – FY 2016" and is dated March 16, 2017. It provides a comprehensive overview of the company's clinical pipeline progress (Phase II studies, pre-clinical development), financial results for the fiscal year 2016 (revenues, cash position, impairment charge), and commercial updates (JETREA sales, FDA approval of new formulation). This structure—covering the entire past fiscal year's performance, strategy, and financial standing in detail—is characteristic of an Annual Report or a comprehensive management discussion accompanying it. However, since it is explicitly labeled as a "Press release" and a "Business Update" providing financial highlights for the year ending December 31, 2016, it functions as the primary communication of the annual results, which aligns closely with the content of a full Annual Report (10-K) but is presented as a press release/update. Given the detailed financial and operational review for a full fiscal year, it is most accurately classified as an Annual Report (10-K) content-wise, or potentially an Earnings Release (ER) if it were only quarterly, but since it covers the full year, 10-K is the closest fit for comprehensive annual review, although it lacks the formal structure of a 10-K filing. If it were a short announcement of the 10-K release, it would be RPA. Since it contains substantial financial and operational details for the full year, it is classified as the comprehensive annual review content, which maps best to 10-K, or potentially MDA if it were purely management discussion. Given the inclusion of full-year financials (€7.1 million revenues, €80.1M cash position), it leans towards the comprehensive annual disclosure, making 10-K the most appropriate category for the *type* of information presented, even if the format is a press release. Revisiting the definitions: 10-K is the 'Official yearly report'. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document covers the full year, not just a quarter, and contains significant detail beyond just highlights. Therefore, 10-K is the best fit for the scope of information provided (FY 2016 update). FY 2016
2017-03-16 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.